medtronic latest results summary
medtronic latest results summary
I'll pull Medtronic's latest earnings data for you. Let me find the ticker and load the recent financial results.
Let me build a clean summary with the latest annual results, latest quarter, and a TTM view, plus margin metrics.
Medtronic's fiscal year ends in April, so FY26 (ended Apr 30, 2026) is the most recently completed full year, and Q4 FY26 (Apr 30, 2026) is the latest reported quarter.
Key takeaways: - FY26 revenue $36.4B, up ~8% YoY vs. $33.5B in FY25 — a meaningful acceleration after several years of flat-to-low growth. - Net income $4.80B vs. $4.66B prior year (+3%) — bottom-line growth lagged revenue, and net margin compressed ~70 bps to 13.2%, likely reflecting deal/integration costs. - Operating margin held at 17.8% flat YoY, with R&D up to $2.87B (vs. $2.73B), consistent with continued pipeline investment. - Q4 FY26 was a standout quarter: revenue $9.81B with gross margin jumping to 75.9% (vs. 65.0% for FY), suggesting a favorable mix or one-time items — worth flagging as it diverges from the FY trend. - TTM (rolling 4Q) is essentially identical to FY26, confirming FY26 just closed.
Caveats / things to dig into: - The Q4 gross margin (75.9%) vs. FY26 full-year (65.0%) gap is large — possible gain on divestiture, royalty, or accounting reclass; the SEC filing would confirm. - The FY26 EBITDA printed $6.85B vs. $9.22B prior year on the annual line — this looks like a depreciation/classification discontinuity in the source rather than a real EBITDA collapse (the TTM EBITDA of $9.09B is more consistent). I'd recommend confirming EBITDA via the 10-K before quoting it externally.
Want me to pull the latest 10-K segment breakdown (Cardiovascular, Medical Surgical, Neuroscience, Diabetes) or FY27 guidance from the most recent earnings release?